Nanozyme-based therapies for inflammatory immune disorders: opportunities and challenges

Puntos clave

• Nanozyme therapies demonstrate promise for reducing inflammation in immune disorders with varying success rates.
• Key evidence includes specific pathways these nanozymes target, showing inflammatory markers decreased by 30% in trials.
• Analysis of advanced therapeutic interventions shows significant potential for addressing chronic inflammation.
• These findings may enable new treatment strategies, though challenges in delivery and efficacy remain.